CUE vs. ASRT, ALLK, CTXR, GNLX, IOBT, PMVP, BYSI, ADAG, ORMP, and RLMD
Should you be buying Cue Biopharma stock or one of its competitors? The main competitors of Cue Biopharma include Assertio (ASRT), Allakos (ALLK), Citius Pharmaceuticals (CTXR), Genelux (GNLX), IO Biotech (IOBT), PMV Pharmaceuticals (PMVP), BeyondSpring (BYSI), Adagene (ADAG), Oramed Pharmaceuticals (ORMP), and Relmada Therapeutics (RLMD). These companies are all part of the "pharmaceutical preparations" industry.
Cue Biopharma (NASDAQ:CUE) and Assertio (NASDAQ:ASRT) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, valuation, analyst recommendations, profitability, media sentiment, community ranking and earnings.
Cue Biopharma has higher earnings, but lower revenue than Assertio. Cue Biopharma is trading at a lower price-to-earnings ratio than Assertio, indicating that it is currently the more affordable of the two stocks.
Cue Biopharma received 39 more outperform votes than Assertio when rated by MarketBeat users. However, 59.09% of users gave Assertio an outperform vote while only 51.81% of users gave Cue Biopharma an outperform vote.
35.0% of Cue Biopharma shares are held by institutional investors. Comparatively, 49.0% of Assertio shares are held by institutional investors. 10.2% of Cue Biopharma shares are held by insiders. Comparatively, 3.2% of Assertio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Cue Biopharma has a beta of 1.98, suggesting that its stock price is 98% more volatile than the S&P 500. Comparatively, Assertio has a beta of 1, suggesting that its stock price has a similar volatility profile to the S&P 500.
Assertio has a net margin of -234.40% compared to Cue Biopharma's net margin of -711.84%. Assertio's return on equity of 10.80% beat Cue Biopharma's return on equity.
Cue Biopharma currently has a consensus price target of $8.00, indicating a potential upside of 359.77%. Assertio has a consensus price target of $5.50, indicating a potential upside of 472.92%. Given Assertio's higher possible upside, analysts plainly believe Assertio is more favorable than Cue Biopharma.
In the previous week, Assertio had 10 more articles in the media than Cue Biopharma. MarketBeat recorded 19 mentions for Assertio and 9 mentions for Cue Biopharma. Cue Biopharma's average media sentiment score of 1.04 beat Assertio's score of 0.61 indicating that Cue Biopharma is being referred to more favorably in the media.
Summary
Assertio beats Cue Biopharma on 9 of the 17 factors compared between the two stocks.
Get Cue Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for CUE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CUE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cue Biopharma Competitors List
Related Companies and Tools
